The past year saw a high profile failure in the emerging field of point-of-care diagnostics. Here’s a science-focused take on why. In October of 2015, biotechnology enthusiasts and investors across Silicon Valley reacted with varying degrees of shock and disappointment as the Wall Street Journal reported that promising diagnostics startup Theranos was hiding serious flaws
READ MORE ARTICLES